The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation
Open accessAbstract
OBJECTIVE: To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB). DATA SOURCES: Thirteen bibliographic databases were searched including MEDLINE, EMBASE and the Cochrane Library. Searches were run from the beginning of 2005 to September 2007. REVIEW METHODS: For the clinical effectiveness review, randomised controlled trials (RCTs) comparing ADV, PEG-alpha-2a and PEG-alpha-2b with currently licensed treatments for CHB, including non-pegylated interferon alpha (IFN-alpha) and lamivudine (LAM), were included. Outcomes included biochemical, histological and virological response to treatment, drug resistance and adverse effects. A systematic review of economic evaluations of antiviral treatments for CHB was conducted. The economic Markov model used in the 2006 report was updated in terms of utility values, discount rates and costs. RESULTS: Of the 82 papers retrieved for detailed screening, eight RCTs were included. Three evaluated ADV, four evaluated PEG-alpha-2b and one (from the original literature search) compared PEG-alpha-2b plus LAM with PEG-alpha-2b monotherapy. No RCTs of PEG-alpha-2a were identified. One ADV trial showed a statistically significant difference between ADV and placebo in terms of ALT response and HBV DNA levels, favouring ADV. Following withdrawal of ADV, levels were similar to those in placebo patients. In the ADV versus ADV plus LAM trial, there was a statistically significant difference in favour of the combination treatment. In the PEG-alpha trials, there were statistically significant differences favouring PEG-alpha-2b plus LAM compared with either one of the drugs given as monotherapy. For the comparison between PEG-alpha-2b and IFN-alpha and the comparison between different staggered regimens of the commencement of PEG-alpha-2b and LAM, there were no statistically significant differences between groups. Four full economic evaluations were identified, in addition to one identified in the original report. Two assessed PEG-alpha-2a; the remainder assessed ADV. PEG-alpha-2a was associated with increased treatment costs and gains in quality-adjusted life expectancy. In a UK study, the incremental cost-effectiveness ratio (ICER) for PEG-alpha-2a was 10,444 pounds per QALY gained compared with LAM. Evaluations of ADV found that LAM monotherapy was dominated; the ICER for ADV monotherapy compared with 'doing nothing' was $19,731. The results of the updated analysis were generally robust to changes in deterministic sensitivity analysis. In a probabilistic sensitivity analysis, the same sequence of treatments was identified as optimal. In a probabilistic sensitivity analysis, PEG-alpha-2b had a probability of being cost-effective of 79% at a willingness-to-pay threshold of 20,000 pounds per QALY, and 86% at a willingness-to-pay threshold of 30,000 pounds per QALY. CONCLUSIONS: Both ADV and PEG-alpha are beneficial for patients with CHB in terms of suppressing viral load, reducing liver damage-associated biochemical activity, inducing HBeAg seroconversion, and reducing liver fibrosis and necroinflammation. The effects of long-term treatment with ADV are generally durable, with relatively low rates of resistance. In most cases, cost-effectiveness estimates were within acceptable ranges. Further research should assess the clinical effectiveness and cost-effectiveness of newer antiviral agents in relation to existing drugs, including the role of initiating treatment with combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Consensus development methods, and their use in clinical guideline development.
Murphy, Black, Lamping, McKee, Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,051
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Evaluating patient-based outcome measures for use in clinical trials.
Fitzpatrick, Davey, Buxton, & Jones (1998) · Health Technology Assessment · doi:10.3310/hta2140 · Cited by 1,715
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Carman, W. F., Hadziyannis, S., Mcgarvey, M. J., Jacyna, M. R., Karayiannis, P., Makris, A., & Thomas, H. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90713-7 · Cited by 1,200
Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E., Claxton, K., & Sculpher, M. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,110
Qualitative research methods in health technology assessment: a review of the literature.
Murphy, Dingwall, Greatbatch, Parker, & Watson (1998) · Health Technology Assessment · doi:10.3310/hta2160 · Cited by 1,107
Viral dynamics in hepatitis B virus infection.
Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C., & McDade, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4398 · Cited by 1,045
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Quality-of-life measures in chronic diseases of childhood
Eiser, C., & Morse, R. (2001) · Health Technology Assessment · doi:10.3310/hta5040 · Cited by 872
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066422 · Cited by 773
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R., Woolacoot, N., & Glanville, J. (2004) · Health Technology Assessment · doi:10.3310/hta8360 · Cited by 697
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 689
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Leung, N. W. Y., Lai, C.-L., Chang, T.-T., Guan, R., Lee, C.-M., Ng, K.-Y., Lim, S.-G., Wu, P.-C., Dent, J. C., Edmundson, S., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.25084 · Cited by 626
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001) · Health Technology Assessment · doi:10.3310/hta5330 · Cited by 580
Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998) · Hepatology · doi:10.1002/hep.510270132 · Cited by 562
Peters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.051 · Cited by 552
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00450.x · Cited by 475
UK population norms for EQ-5DPreprint
Kind, P., Hardman, G., & Macran, S. (1999) · RePEc: Research Papers in Economics · Cited by 443
Chu, C.-M., Karayiannis, P., Fowler, M. J. F., Monjardino, J., Liaw, Y.-F., & Thomas, H. C. (1985) · Hepatology · doi:10.1002/hep.1840050315 · Cited by 419
Davis, Bamford, Wilson, Ramkalawan, Forshaw, & Wright (1997) · Health Technology Assessment · doi:10.3310/hta1100 · Cited by 407
Brocklebank, D., Ram, F., Wright, J., Barry, P., Cates, C., Davies, L., Douglas, G., Muers, M., Smith, D., & White, J. (2001) · Health Technology Assessment · doi:10.3310/hta5260 · Cited by 401
Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials
Song, F., & Glenny, A.-M. (1998) · Journal of British Surgery · doi:10.1046/j.1365-2168.1998.00883.x · Cited by 372
Churchill, R., Hunot, V., Corney, R., Knapp, M., McGuire, H., Tylee, A., & Wessely, S. (2002) · Health Technology Assessment · doi:10.3310/hta5350 · Cited by 368
Statistical assessment of the learning curves of health technologies
Ramsay, C. R., Grant, A. M., Wallace, S. A., Garthwaite, P. H., Monk, A. F., & Russell, I. T. (2001) · Health Technology Assessment · doi:10.3310/hta5120 · Cited by 353
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Brañas, Jordan, Fry-Smith, Burls, & Hyde (2000) · Health Technology Assessment · doi:10.3310/hta4270 · Cited by 330
Lok, A. S. F., Lai, C.-L., Wu, P.-C., Leung, E. K. Y., & Lam, T.-S. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90613-5 · Cited by 326
Routine preoperative testing: a systematic review of the evidence.
Munro, Booth, & Nicholl (1997) · Health Technology Assessment · doi:10.3310/hta1120 · Cited by 322
Bennett, W. G., Inoue, Y., Beck, J. R., Wong, J. B., Pauker, S. G., & Davis, G. L. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00001 · Cited by 315
Hampson, S. E., Skinner, T. C., Hart, J., Storey, L., Gage, H., Foxcroft, D., Kimber, A., Shaw, K., & Walker, J. (2001) · Health Technology Assessment · doi:10.3310/hta5100 · Cited by 311
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., Lin, D.-Y., Sheen, I.-S., Chen, T.-J., & Pao, C. C. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90919-4 · Cited by 309
Methods for the analysis of quality-of-life and survival data in health technology assessment.
Billingham, Abrams, & Jones (1999) · Health Technology Assessment · doi:10.3310/hta3100 · Cited by 307
Elkan, Kendrick, Hewitt, Robinson, Tolley, Blair, Dewey, Williams, & Brummell (2000) · Health Technology Assessment · doi:10.3310/hta4130 · Cited by 297
Bricker, L., Garcia, J., Henderson, J., Mugford, M., Neilson, J. P., Roberts, T. E., & Martin, M. A. (2000) · PubMed · Cited by 293
Health-state utilities and quality of life in hepatitis C patients
Chong, C. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)06054-9 · Cited by 277
King, Sibbald, Ward, Bower, Lloyd, Gabbay, & Byford (2000) · Health Technology Assessment · doi:10.3310/hta4190 · Cited by 274
Chan, H. L.-Y., Leung, N. W.-Y., Hui, A. Y., Wong, V. W.-S., Liew, C.-T., Chim, A. M.-L., Chan, F. K.-L., Hung, L. C.-T., Lee, Y.-T., Tam, J. S.-L., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00006 · Cited by 272
EASL International Consensus Conference on Hepatitis C
Marcellin, P. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80366-3 · Cited by 268
Flink, H. J., van Zonneveld, M., Hansen, B. E., de Man, R. A., Schalm, S. W., Janssen, H. L. A., & for the HBV 99-01 Study Group* (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00418.x · Cited by 262
Management of chronic hepatitis B
Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00431-2 · Cited by 257
MacLeod, Grant, Donaldson, Khan, Campbell, Daly, Lawrence, Wallace, Vale, Cody, et al. (1998) · Health Technology Assessment · doi:10.3310/hta2050 · Cited by 254
Monitoring blood glucose control in diabetes mellitus: a systematic review.
Coster, Gulliford, Seed, Powrie, & Swaminathan (2000) · Health Technology Assessment · doi:10.3310/hta4120 · Cited by 245
Newborn screening for inborn errors of metabolism: a systematic review.
Seymour, Thomason, Chalmers, Addison, Bain, Cockburn, Littlejohns, Lord, & Wilcox (1997) · Health Technology Assessment · doi:10.3310/hta1110 · Cited by 234
Treatment of established osteoporosis: a systematic review and cost-utility analysis
Kanis, J. A., Brazier, J. E., Stevenson, M., Calvert, N. W., & Lloyd Jones, M. (2002) · Health Technology Assessment · doi:10.3310/hta6290 · Cited by 229
False-negative results in screening programmes: systematic review of impact and implications.
Petticrew, Sowden, Lister-Sharp, & Wright (2000) · Health Technology Assessment · doi:10.3310/hta4050 · Cited by 225
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B
Jury, E. (2003) · Cited by 214
A systematic review of discharge arrangements for older people
Parker, S. G., Peet, S. M., McPherson, A., Cannaby, A. M., Abrams, K., Baker, R., Wilson, A., Lindesay, J., Parker, G., & Jones, D. R. (2002) · Health Technology Assessment · doi:10.3310/hta6040 · Cited by 212
Home treatment for mental health problems: a systematic review
Burns, T., Knapp, M., Catty, J., Healey, A., Henderson, J., Watt, H., & Wright, C. (2001) · Health Technology Assessment · doi:10.3310/hta5150 · Cited by 211
Chilcott, J., Lloyd Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C., & Tappenden, P. (2003) · Health Technology Assessment · doi:10.3310/hta7040 · Cited by 210
Natural history of hepatitis B: Epidemiology
(2010) · Hepatitis C and B · doi:10.4324/9780203357187_chapter_17 · Cited by 204
Screening for gestational diabetes: a systematic review and economic evaluation
Scott, D. A., Loveman, E., McIntyre, L., & Waugh, N. (2002) · Health Technology Assessment · doi:10.3310/hta6110 · Cited by 203
Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
Davies, Cronin, Gill, Greengross, Hickman, & Normand (2000) · Health Technology Assessment · doi:10.3310/hta4030 · Cited by 201
'Early warning systems' for identifying new healthcare technologies.
Robert, Stevens, & Gabbay (1999) · Health Technology Assessment · doi:10.3310/hta3130 · Cited by 189
Mowatt, G., Vale, L., Perez, J., Wyness, L., Fraser, C., MacLeod, A., Daly, C., & Stearns, S. C. (2003) · Health Technology Assessment · doi:10.3310/hta7020 · Cited by 179
Shepherd, Waugh, & Hewitson (2000) · Health Technology Assessment · doi:10.3310/hta4330 · Cited by 175
van Nunen, A. B., Hansen, B. E., Suh, D. J., Löhr, H. F., Chemello, L., Fontaine, H., Heathcote, J., Song, B. C., Janssen, H. L. A., de Man, R. A., et al. (2003) · Gut · doi:10.1136/gut.52.3.420 · Cited by 172
Costs and benefits of community postnatal support workers: a randomised controlled trial
Morrell, Spiby, Stewart, Walters, & Morgan (2000) · Health Technology Assessment · doi:10.3310/hta4060 · Cited by 166
Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young, B., Wailoo, A. J., & Lewis, I. J. (2003) · Health Technology Assessment · doi:10.3310/hta7050 · Cited by 163
Lewis, R., Whiting, P., ter Riet, G., O'Meara, S., & Glanville, J. (2001) · Health Technology Assessment · doi:10.3310/hta5140 · Cited by 163
Levy, A. R., Kowdley, K. V., Iloeje, U., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N., & Briggs, A. H. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00297.x · Cited by 161
Sung, J. J. �., Lai, J.-Y., Zeuzem, S., Chow, W.-C., Heathcote, E. J., Perrillo, R. P., Brosgart, C. L., Woessner, M. A., Scott, S. A., Gray, D. F., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.026 · Cited by 154
Liquid-based cytology in cervical screening: a rapid and systematic review.
Payne, Chilcott, J. B., & McGoogan (2000) · Health Technology Assessment · doi:10.3310/hta4180 · Cited by 153
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.
Meads, C., Cummins, C., Jolly, K. B., Stevens, A. J., Burls, A., & Hyde (2000) · Health Technology Assessment · doi:10.3310/hta4230 · Cited by 152
Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.
Zeuner, Ades, Karnon, J. D., Brown, Dezateux, C. A., & Anionwu (1999) · Health Technology Assessment · doi:10.3310/hta3110 · Cited by 152
Ratcliffe, J., Longworth, L., Young, T., Bryan, S., Burroughs, A. K., & Buxton, M. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.31345 · Cited by 149
Bryant, J., Cave, C., Mihaylova, B., Chase, D., McIntyre, L., Gerard, K., & Milne, R. (2002) · Health Technology Assessment · doi:10.3310/hta6180 · Cited by 144
Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis
Kanwal, F., Gralnek, I. M., Martin, P. B., Dulai, G. S., Farid, M., & Spiegel, B. M. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-10-200505170-00007 · Cited by 137
Boland, A., Dundar, Y., Bagust, A., Haycox, A. R., Hill, R. A., Mujica-Mota, R. E., Walley, T., & Dickson, R. (2003) · Health Technology Assessment · doi:10.3310/hta7150 · Cited by 136
What role for statins? A review and economic model.
Ebrahim, S. B. J., Smith, G. D., McCabe, Payne, Pickin, Sheldon, T., Lampe, F. C., Sampson, F. C., Ward, S. E., & Wannamethee, S. G. (1999) · Health Technology Assessment · doi:10.3310/hta3190 · Cited by 134
Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
Dusheiko, G. M., & Roberts, J. A. (1995) · Hepatology · doi:10.1002/hep.1840220636 · Cited by 133
Issues in methodological research: perspectives from researchers and commissioners
Lilford, R. J., Richardson, A., Stevens, A., Fitzpatrick, R., Edwards, S., Rock, F., & Hutton, J. L. (2001) · Health Technology Assessment · doi:10.3310/hta5080 · Cited by 132
Kinley, H., Czoski‐Murray, C., George, S., McCabe, C. J., Primrose, J. M., Reilly, C. J., Wood, R., Nicolson, P., Healy, C., Read, S., et al. (2001) · Health Technology Assessment · doi:10.3310/hta5200 · Cited by 129
Roderick, P. J., Davies, R. J., Raftery, J., Crabbe, D., Pearce, R., Bhandari, P., & Patel, P. (2003) · Health Technology Assessment · doi:10.3310/hta7060 · Cited by 124
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation
Burls, A., Clark, W. K., Stewart, T., Preston, C., Bryan, S., Jefferson, T., & Fry-Smith, A. (2002) · Health Technology Assessment · doi:10.3310/hta6090 · Cited by 121
Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.
Harris, Kelly, K., Berry, Hutton, Roderick, Cullingworth, Gathercole, O’Connor, Boyce, & Smith (1998) · Health Technology Assessment · doi:10.3310/hta2180 · Cited by 121
French, Cowan, F. M., Mansour, Stephen Morris, A., Procter, Hughes, Robinson, & Guillebaud (2000) · Health Technology Assessment · doi:10.3310/hta4070 · Cited by 120
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg, A. J., Bryant, J., & Milne, R. (2000) · Health Technology Assessment · doi:10.3310/hta4090 · Cited by 118
Buster, E. H. C. J., Hansen, B. E., Buti, M., Delwaide, J., Niederau, C., Michielsen, P. P., Flisiak, R., Zondervan, P. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Hepatology · doi:10.1002/hep.21723 · Cited by 115
Berry, E., Kelly, S., Westwood, M. E., Davies, L. M., Gough, M. J., Bamford, J., Meaney, J. F., Airey, C. M., Cullingworth, J., Barbieri, M., et al. (2002) · Health Technology Assessment · doi:10.3310/hta6070 · Cited by 112
Sculpher, M., Petticrew, M. P., Kelland, J., Elliott, R. A., Holdright, D. R., & Buxton, M. J. (1998) · Health Technology Assessment · doi:10.3310/hta2100 · Cited by 106
Stein, K., Dalziel, K., Walker, A., McIntyre, L., Jenkins, B., Horne, J., Royle, P., & Round, A. (2002) · Health Technology Assessment · doi:10.3310/hta6310 · Cited by 103
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment
Hyde, C., Wake, B., Bryan, S., Barton, P., Fry-Smith, A., Davenport, C. F., & Song, F. (2002) · Health Technology Assessment · doi:10.3310/hta6020 · Cited by 90
Elliott, R. A., Payne, K., Moore, J. K., Davies, L. M., Harper, N. J. N., Leger, A. S. S., Moore, E. W., Thoms, G., Pollard, B. J., McHugh, G. A., et al. (2002) · Health Technology Assessment · doi:10.3310/hta6300 · Cited by 89
van Zonneveld, M., Flink, H. J., Verhey, E., Şentürk, H., Zeuzem, S., Akarca, U. S., Çakaloğlu, Y., Simon, K. A., So, T. M. K., Gerken, G., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02453.x · Cited by 86
McDonagh, Bachmann, Golder, S., Kleijnen, J., & ter Riet, G. (2000) · Health Technology Assessment · doi:10.3310/hta4300 · Cited by 79
Zhao, H., Kurbanov, F., Wan, M.-B., Yin, Y.-K., Niu, J. Q., Hou, J., Wei, L., Wang, G. ‐., Tanaka, Y., Mizokami, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511042 · Cited by 76
A study of the methods used to select review criteria for clinical audit
Hearnshaw, H., Harker, R., Cheater, F., Baker, R., & Grimshaw, G. (2001) · Health Technology Assessment · doi:10.3310/hta6010 · Cited by 74
Hui, C., Zhang, H., Lee, N. P. Y., Chan, W., Yueng, Y., Leung, K.-W., Lu, L., Leung, N. W. Y., Lo, C., Fan, S.-T., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.023 · Cited by 56
Crowley, S. J., Tognarini, D. P., Desmond, P. V., LEES, M., & Saal, G. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02673.x · Cited by 49
Yao, G., Chen, C., Lu, W., Ren, H., Tan, D., Wang, Y., Xu, D., Jiang, Z., Liu, J., Xu, D. Z., et al. (2008) · Hepatology International · doi:10.1007/s12072-007-9043-0 · Cited by 45
Brooks, E. A., Lacey, L. F., Payne, S. L., & Miller, D. W. (2001) · PubMed · Cited by 36
Pojoga, C., cu, D. L. D., Pascu, O., Grigorescu, M. D., Radu, C., & Damian, D. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200401000-00005 · Cited by 35
Chan, H. L., Wong, V. W., Chim, A. M., Choi, P. C., Chan, H., Hui, A., Wong, G. L., & Sung, J. J. �. (2007) · PubMed · Cited by 30
Sullivan, S. D., Veenstra, D. L., Chen, P., Chang, T., Chuang, W., Tsai, C., & Patel, K. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04539.x · Cited by 28
Cited by
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Development of a New Patient-Reported Outcome Measure for Breast Surgery: The BREAST-Q
Pusic, A. L., Klassen, A. F., Scott, A. M., Klok, J. A., Cordeiro, P. G., & Cano, S. J. (2009) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181aee807 · Cited by 1,873
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.054 · Cited by 1,854
Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.005 · Cited by 782
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705
Metadata
- Authors
- Jones, J., Shepherd, J., Baxter, L., Gospodarevskaya, E., Hartwell, D., Harris, P., & Price, A.
- Venue
- Health Technology Assessment
- Published
- 2009-07
- Volume
- 13
- Issue
- 35
- Pages
- 1-172, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2122087900
- Cited by
- 357
- References
- 107
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.